IL-15对体外培养的DC致敏的T淋巴细胞的作用研究  

A Study on IL- 15 as an Adjuvant for DC Vaccine Strategy to T Cell Response in Vitro

作　　者：赵煜[1] 张涛[1] 刘焕义[1] 徐红玉[1] 杨波[1] 苏晓妹[1] 朱亚杰[1] 刘桢[1] 

机构地区：[1]中国人民解放军成都军区总医院肿瘤中心,四川成都610083

出　　处：《湖北民族学院学报（医学版）》2014年第3期1-4,共4页Journal of Hubei Minzu University(Medical Edition)

摘　　要：目的通过与IL-2进行比较,观察IL-15激活T细胞反应,增强DC细胞疫苗抗肿瘤的免疫反应。方法将骨髓来源的树突状细胞(BMDCs)皮下注射小鼠作为初次免疫,14d后取小鼠脾脏,制备淋巴细胞,与细胞因子(IL-2、IL-15)和BMDCs共同培养作为再次免疫,产生细胞毒T淋巴细胞(CTL)。流式细胞术检测细胞因子(IL-2或IL-15)联合BMDCs刺激小鼠淋巴细胞CD62L、CD69、CD44的表达情况;采用Cr51释放实验检测CTL对Levis肺癌细胞的杀伤作用;采用酶联免疫斑点实验(ELISPOT)检测分泌干扰素γ(IFN-γ)细胞亚群比例。结果IL-15联合BMDCs疫苗上调CD8+T细胞表达CD69+、CD44+,增强对肿瘤细胞的杀伤活性,并能产生更多的IFN-γ分泌细胞。结论 IL-15可能较IL-2更能增强DC疫苗抗肿瘤的免疫反应,为IL-15和DC疫苗的联合免疫治疗提供重要的试验依据和临床前研究的理论基础。Objective Interleukin-15 （IL-15）, compared with IL-2, was used as a potent adju- vant for dendritic cells （DCs）-directed vaccine strategy to activate T cell responses in vitro. Methods Bone marrow-derived DCs （BMDCs） were pulsed with tumor antigens and were in- jected subcutaneously into mice, 14 days later, splenocytes were harvested and cultured in vitro with BMDCs to stimulate lymphocyte responses in the presence of IL-2 or IL-15 for 7 days. The activated T lymphocytes were examined by flow cytometric analysis, interferon-γ/ （IFN-1, ） enzyme-linked immunospot and cytotoxicity assays.Results IL-15 could enhance the expression of CD69^＋ and CD44^＋,cytotoxicity and IFN-,y production.Cenclusien The use of IL-15 acting as a potent adjuvant for DC-directed vaccine strategy may offer alternative choices for the immunotherauv of cancer.

关 键 词：白细胞介素15 白细胞介素2 CD8+T细胞 树突状细胞 

分 类 号：R735.7[医药卫生—肿瘤]